First Trust NYSE® Arca® Biotechnology Index Fund (FBT)

	Printer Friendly Page
	Fact Sheet
	Summary Prospectus
	Monthly Performance Report
	Investor Guide
	A Guide To Thematic ETFs

Fund Summary

2022 Estimated Capital Gain Distributions
Certain First Trust Exchange-Traded Funds are expected to pay a long-term capital gain distribution in December. For a list of exchange-traded funds expected to pay a capital gain distribution, please click here. Final determination of the source and tax status of all distributions paid in the current year are to be made after year-end and could differ from the expectations noted above.
On October 24th, 2022, the Board of Trustees of First Trust's ETFs approved a management fee breakpoint policy that will make all ETFs in the complex eligible for a reduction in the management fee charged on assets that exceed certain AUM thresholds. The goal of this policy is to offer reductions in management fees paid by shareholders of larger First Trust ETFs through a process that is transparent and understandable for all investors.
Effective November 1st, 2022, the management fee paid by any First Trust ETF with assets exceeding $2.5 Billion will decrease, with larger and increased reductions for assets above $5 Billion, $7.5 Billion, $10 Billion and $15 Billion.

Full details of the policy and additional breakpoint levels can be seen in each fund’s Statement of Additional Information.

Investment Objective/Strategy - The First Trust NYSE® Arca® Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE® Arca Biotechnology Index.

There can be no assurance that the Fund's investment objectives will be achieved.